Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype

Lung cancer remains the leading cause of cancer-related mortality worldwide [1]. The 5  year survival for patients with non-small cell lung cancer (NSCLC), the most common form of the disease, is 10−20% [2,3]. Despite advances in treatment options in recent years, survival rates have changed little [3,4].

Source: Lung Cancer - June 1, 2020 Category: Cancer & Oncology Authors: Isabella Fornacon-Wood, Corinne Faivre-Finn, James P.B. O ’Connor, Gareth J. Price Source Type: research